Stryker Corporation (SYK) Holdings Trimmed by Well Done LLC

Well Done LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 13.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,005 shares of the medical technology company’s stock after selling 475 shares during the quarter. Well Done LLC’s holdings in Stryker were worth $466,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Sawyer & Company Inc acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $125,000. Sit Investment Associates Inc. grew its position in shares of Stryker by 114.3% in the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 440 shares during the last quarter. Oak Point Wealth Management acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $145,000. San Francisco Sentry Investment Group CA grew its position in shares of Stryker by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares during the last quarter. Finally, Dubuque Bank & Trust Co. acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $164,000. Institutional investors own 74.71% of the company’s stock.

Stryker Corporation (NYSE:SYK) opened at $159.87 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.59 and a current ratio of 2.29. The firm has a market cap of $59,894.02, a P/E ratio of 24.63, a price-to-earnings-growth ratio of 2.30 and a beta of 0.70. Stryker Corporation has a one year low of $124.89 and a one year high of $170.00.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.01. The company had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. Stryker’s revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.78 earnings per share. equities analysts expect that Stryker Corporation will post 7.12 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s dividend payout ratio is currently 70.15%.

Several analysts have recently commented on SYK shares. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and increased their price target for the company from $161.00 to $173.00 in a research report on Thursday, November 16th. SunTrust Banks reiterated a “buy” rating and issued a $161.00 price target on shares of Stryker in a research report on Friday, November 17th. Wells Fargo & Co raised their target price on shares of Stryker from $160.00 to $166.00 in a research report on Friday, October 27th. Barclays raised their target price on shares of Stryker from $137.00 to $148.00 and gave the stock an “underweight” rating in a research report on Friday, October 27th. Finally, Leerink Swann raised their target price on shares of Stryker from $177.00 to $184.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $162.50.

In other Stryker news, VP William E. Berry, Jr. sold 1,306 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $164.42, for a total transaction of $214,732.52. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Graham A. Mclean sold 2,984 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $160.53, for a total transaction of $479,021.52. Following the transaction, the insider now directly owns 9,100 shares in the company, valued at approximately $1,460,823. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,840 shares of company stock worth $2,749,989. 7.40% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Stryker Corporation (SYK) Holdings Trimmed by Well Done LLC” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/18/stryker-corporation-syk-holdings-trimmed-by-well-done-llc.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply